{"id":42972,"date":"2024-11-18T07:00:00","date_gmt":"2024-11-18T06:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/us\/press-releases\/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434\/"},"modified":"2024-11-18T07:00:00","modified_gmt":"2024-11-18T06:00:00","slug":"bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/us\/press-releases\/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434\/","title":{"rendered":"Bylvay\u00ae (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS"},"content":{"rendered":"